islatravir: Clinical Trials

8 trials of islatravir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 withdrawn, 1 active not recruiting, 1 recruiting. 8 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 28Completed 4, Withdrawn 2, Active not recruiting 1, Recruiting 1
Phase 31Recruiting 1

Follow islatravir: new trials by email Literature Review of islatravir trials Research Report on islatravir

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
ISL, ULO, BIC/FTC/TAF - Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Phase 2 / Phase 3RecruitingMerck Sharp & Dohme LLC5702025-12-182026-11-04
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
ISL, ULO, BIC/FTC/TAF - Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Phase 2Active not recruitingMerck Sharp & Dohme LLC1502025-04-142025-10-16
Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)
Islatravir, Placebo - Human Immunodeficiency Virus, HIV
Phase 2WithdrawnMerck Sharp & Dohme LLC2024-01-042023-11-24
A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)
Islatravir - Human Immunodeficiency Virus (HIV) Infections
Phase 2WithdrawnMerck Sharp & Dohme LLC2022-10-172022-10-17
Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
Islatravir, Ulonivirine, BIC/FTC/TAF - HIV-1 Infection
Phase 2CompletedMerck Sharp & Dohme LLC1612021-03-092026-01-26
Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)
DOR/ISL - HIV-1 Infection
Phase 2CompletedMerck Sharp & Dohme LLC422020-11-262024-01-31
Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
Islatravir, Placebo - HIV-1 Infection
Phase 2CompletedMerck Sharp & Dohme LLC2422019-09-192025-07-18
Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
Islatravir, Placebo to Islatravir, Doravirine - HIV-1 Infection
Phase 2CompletedMerck Sharp & Dohme LLC1232017-11-272023-03-29

Conditions studied

Acquired Immunodeficiency Syndrome (4)  ·  Infections (3)

Sponsors

Merck Sharp & Dohme LLC (8)

Countries

United States (6)  ·  France (3)  ·  South Africa (3)  ·  Chile (2)  ·  Switzerland (2)  ·  Argentina (1)  ·  Australia (1)  ·  Canada (1)  ·  Guatemala (1)  ·  Israel (1)  ·  Italy (1)  ·  Mexico (1)  ·  Puerto Rico (1)  ·  Russia (1)  ·  Spain (1)

Results publications

PMID 33540481, PMID 34000227, PMID 35972855, PMID 40260892, PMID 40327547, PMID 41789892

NIH funding

2019 (2), 2017 (1), 2025 (1)